Use of Proprotein Converse Subtilisin/Kexin Type 9 Inhibitor to Treat Cholesterol Crystal Embolisms after Catheterization: A Report of Three Cases.

Tomoi, Yusuke; Soga, Yoshimitsu; Imada, Kazuaki; Kodama, Kenji; Katsuki, Tomonori; Hiramori, Seiichi; Ando, Kenji

Tomoi, Yusuke; Soga, Yoshimitsu; Imada, Kazuaki; Kodama, Kenji; Katsuki, Tomonori; Hiramori, Seiichi; Ando, Kenji.

Afiliación

Tomoi Y; Department of Cardiology, Kokura Memorial Hospital, Japan.
Soga Y; Department of Cardiology, Kokura Memorial Hospital, Japan.
Imada K; Department of Cardiology, Kokura Memorial Hospital, Japan.
Kodama K; Department of Cardiology, Kokura Memorial Hospital, Japan.
Katsuki T; Department of Cardiology, Kokura Memorial Hospital, Japan.
Hiramori S; Department of Cardiology, Kokura Memorial Hospital, Japan.
Ando K; Department of Cardiology, Kokura Memorial Hospital, Japan.

Intern Med ; 61(6): 857-860, 2022 Mar 15.

Article en En | MEDLINE | ID: mdl-34471031

Asunto(s)

Embolia por Colesterol; Proproteína Convertasa 9; Cateterismo; LDL-Colesterol; Embolia por Colesterol/tratamiento farmacológico; Humanos; Proproteína Convertasas; Subtilisina

Palabras clave

anti-PCSK9 antibody; catheterization; cholesterol crystal embolism; renal failure

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Embolia por Colesterol / Proproteína Convertasa 9 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Intern Med Asunto de la revista: MEDICINA INTERNA Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google